CSF-1R Kinase Inhibitor Patent Grant

Tue, 21 Apr 2026 10:47:50 +0000
Intellectual Property

USPTO granted patent US12605375B2 to Shanghai Runshi Medical Technology Co., Ltd. covering the use of a CSF-1R kinase inhibitor compound for treating diseases related to CSF-1R kinase signal transduction and for regulating immunization. The patent claims 8 total claims. The compound demonstrated superior inhibition of CSF-1R kinase activity and anti-tumor efficacy compared to marketed drug Pexidartinib in preclinical studies.